Drug Interactions between abiraterone and encorafenib
This report displays the potential drug interactions for the following 2 drugs:
- abiraterone
- encorafenib
Interactions between your drugs
abiraterone encorafenib
Applies to: abiraterone and encorafenib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abiraterone, which is partially metabolized by the isoenzyme. In healthy subjects administered a single 1000 mg dose of abiraterone following pretreatment with the potent CYP450 3A4 inducer rifampin (600 mg daily for 6 days), mean abiraterone systemic exposure (AUC) decreased by 55%. In addition, when two or more medications with similar adverse effect profiles are given concurrently, the likelihood of experiencing these adverse reactions may be increased. For example, coadministration with other agents that can prolong the QT interval (e.g., apalutamide, encorafenib, enzalutamide) may result in additive effects and an increased risk of ventricular arrhythmias like torsade de pointes.
MANAGEMENT: Concomitant use of abiraterone acetate with potent CYP450 3A4 inducers should generally be avoided. Otherwise, an increase in dosing frequency for abiraterone acetate from once daily to twice daily during the coadministration period may be considered, although this dosage adjustment has not been studied clinically. The dosage should be adjusted back to the previous level when the CYP450 3A4 inducer is discontinued. If abiraterone acetate is part of a combination pill, the regimen may need to be split into its individual components to allow for changes in abiraterone acetate dosing without affecting the other component(s). If the CYP450 3A4 inducer also carries a risk of prolonging the QT interval, then obtaining more frequent electrocardiograms (ECGs) to monitor the QT interval may be advisable. Patients should be counseled to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, syncope, palpitations, irregular heartbeat, and/or shortness of breath.
Drug and food interactions
encorafenib food
Applies to: encorafenib
You should preferably avoid consumption of grapefruit and grapefruit juice while taking encorafenib. Grapefruit and grapefruit juice can significantly increase the blood levels of encorafenib. This may increase the risk of serious side effects such as bleeding complications, eye and vision problems, liver problems, irregular heart rhythm, and development of new skin cancers. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
abiraterone food
Applies to: abiraterone
This interaction does not apply to abiraterone acetate (Yonsa) 125 mg tablets, which can be taken with or without food.
Taking abiraterone with food increases the amount of medicine that gets absorbed by the body for certain formulations. This may increase the risk of side effects such as high blood pressure, water retention, and a condition called hypokalemia (low blood potassium), which in severe cases can lead to muscle weakness, paralysis, breathing and swallowing difficulties (due to muscle paralysis), and irregular heart rhythm. You should take abiraterone once a day on an empty stomach. No food should be eaten for at least two hours before and one hour after taking abiraterone. Let your doctor know if you experience nausea, vomiting, constipation, abdominal cramping, confusion, dizziness, lightheadedness, fainting, muscle weakness, muscle cramps, numbness or tingling, rapid heartbeat, chest pain, and/or swelling in the legs or feet, as these may be symptoms of hypokalemia or excessive effects of abiraterone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.